Safety and Efficacy of Vadadustat Versus Darbepoetin Alfa for Chronic Kidney Disease-Related Anemia in Patients Receiving Dialysis by Baseline Erythropoiesis-Stimulating Agent Dose. [PDF]
Hemodial IntABSTRACT Introduction Erythropoiesis‐stimulating agents (ESAs) and iron supplementation are standard treatments for chronic kidney disease (CKD)–related anemia. Targeting higher hemoglobin values in CKD increases cardiovascular risk. Whether the increased risk is from higher ESA doses or higher hemoglobin levels is uncertain, but alternative therapies ...
Jardine A +9 more
europepmc +2 more sources
Potential Association Between Darbepoetin Alfa Administration and Reduced Proteinuria in Real-World Clinical Practice: A Post Hoc Analysis of the BRIGHTEN Study. [PDF]
Nephrology (Carlton)The study investigated the association between darbepoetin alfa (DA) dosage and urinary protein levels in real‐world chronic kidney disease (CKD) patients. High‐dose DA administration was associated with reduced proteinuria, particularly in diabetic kidney disease (DKD) patients with high erythropoiesis resistance index (ERI‐1B) values, suggesting ...
Hirashio S +3 more
europepmc +2 more sources
Hematology, Transfusion and Cell Therapy, 2023 Objective: This study aimed to evaluate the clinical efficacy of epoetin alfa and darbepoetin alfa in patients with myelodysplastic syndromes (MDS) in the real-life setting.
Müzeyyen Aslaner Ak +10 more
doaj +1 more source
JR‐131, a Biosimilar of Darbepoetin Alfa, for the Treatment of Hemodialysis Patients With Renal Anemia: A Randomized, Double‐Blinded, Parallel‐Group Phase 3 Study [PDF]
Therapeutic Apheresis and Dialysis, 2020 Kazuhiko Tsuruya, Hidetomo Nakamoto
exaly +2 more sources
Pharmacology of darbepoetin alfa [PDF]
Nephrology Dialysis Transplantation, 2007 The distinct molecular structure of darbepoetin alfa, in both its amino acid sequence and its carbohydrate content, results in a biologic profile with lower binding affinity, longer circulating half-life, and higher in vivo potency compared with the epoetins.
Iain C, Macdougall +2 more
openaire +2 more sources
Darbepoetin Alfa (Aranesp) [PDF]
Baylor University Medical Center Proceedings, 2002 The Food and Drug Administration (FDA) approved darbepoetin alfa (Aranesp) for treatment of anemia as sociated with chronic renal failure (CRF) in patients on dialysis and patients not on dialysis (1). The manufacturer of the drug also filed an application with the FDA on September 18, 2001, to receive an indication for treatment of anemia in patients ...
John, Powell, Cheryle, Gurk-Turner
openaire +2 more sources
Фармация и фармакология (Пятигорск), 2021 Clinical trials conducted in various countries indicate that the use of epoetin alfa in patients with nephrogenic anemia in chronic kidney disease can increase the effectiveness of treatment, reduce the incidence of cardiovascular and infectious ...
I. S. Krysanov +3 more
doaj +1 more source
Darbepoetin in chronic kidney disease and dialysis patients; an updated review of outcomes [PDF]
Journal of Nephropharmacology, 2020 Individuals with chronic renal failure in stage three and after demonstrate anemia as a frequent complication. Although target hemoglobin levels remain debatable in pre-dialysis and dialysis patients, correction of anemia with erythropoiesis-stimulating ...
Tarun Kumar Jeloka +4 more
doaj +1 more source
Belzutifan for Metastatic TFE3-Rearranged Renal Cell Carcinoma With Pulmonary Metastases: A Case Report. [PDF]
IJU Case RepABSTRACT Introduction Belzutifan is effective in patients with previously treated advanced clear cell renal cell carcinoma. However, evidence for its use in non‐clear cell renal cell carcinoma remains limited. Case Presentation A 33‐year‐old Japanese woman underwent total nephrectomy for a 10‐cm renal tumor with lung metastases.
Nakamura K +9 more
europepmc +2 more sources
USE OF DARBEPOETIN ALFA (ARANESP®) FOR ANEMIA TREATMENT IN CHILDREN WITH CHRONIC KIDNEY DISEASE – CLINICAL EXPERIENCE OF BULGARIAN PEDIATRIC GROUP [PDF]
Journal of IMAB, 2017 Darbepoetin alfa (DA) is indicated for treatment of symptomatic anemia related to chronic kidney disease (CKD) in adult and pediatric patients. In comparison with the recombinant human erythropoietin (rHuEpo), darbepoetin alfa has two additional ...
Maria Gaydarova +3 more
doaj +1 more source